As part of the agreement, EchelonDx is providing expertise using its precise PrenatalDx technology to help enhance the data analysis and reporting capabilities for Cradle’s comprehensive fetal genetic analysis and health screening solutions.
The new funding will be used to support commercial expansion of the company's Unity prenatal screening test to all US states as well as research and development for future diagnostics.
This month's Product News section features products from Qiagen, ELITechGroup Biomedical Systems, and DiaSorin Molecular.
The updated software includes an innovative method for processing samples and is designed for larger batches of 48 samples, versus the current 16 samples.
Read More
The test can help physicians identify women at increased risk for premature delivery as early as 19 weeks into the pregnancy.
Read MoreThe test’s associated proprietary software is now cleared for the analysis of data from next-generation sequencing, as well as from qPCR.
Read More
Delivering accurate results in 5 minutes, the hCG test uses a lateral-flow platform that incorporates an integrated buffer delivery mechanism.
Read More
The transaction represents a total enterprise value of approximately $371 million, including Sequenom’s net indebtedness.
Read More
Results are delivered in 10 minutes.
Read MoreIn a clinical validation study, Sequenom’s laboratory-developed noninvasive prenatal test was shown to exhibit high resolution, sensitivity, and specificity.
Read More
The company seeks to use microarray analysis to tap an underserved market.
Read More
Acquisition gives PE access to an innovative noninvasive prenatal testing solution under development, expanding the company’s maternal–fetal health portfolio.
Read More
CombiMatrix now markets four prenatal and postnatal analysis tests in New York State.
Read MoreCombiMatrix Corp, a molecular diagnostics company specializing in DNA-based testing services for pre- and postnatal developmental disorders, has launched its Targeted Array for Prenatal Analysis.
Read More
The settlement between Illumina and Sequenom creates a pool for joint use of the companies’ intellectual properties in noninvasive prenatal testing.
Read More
With its acquisition of Ariosa Diagnostics, Roche enters the market for noninvasive prenatal testing and cell-free DNA testing services.
Read More
The Society for Maternal-Fetal Medicine (SMFM) has reviewed evidence on the emerging use of noninvasive prenatal testing, concluding that recent research is not yet sufficient to change current practice recommendations.
Read MoreIn a recent study of noninvasive prenatal testing using cell-free DNA compared to standard prenatal aneuploidy screening, the noninvasive test significantly reduced the rate of false-positive results for the detection of fetal trisomies 21 and 18.
Read More